URGN UroGen Pharma Ltd
- Stocks
- Healthcare
- NASDAQ: URGN
Price (delayed)
$23.05
Market cap
$1.07B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.12
Enterprise value
$1.1B
Relative Growth:
Rel. Growth:
50
Relative Strength:
Rel. Strength:
83
Relative Valuation:
Rel. Valuation:
9
Relative Profitability:
Rel. Profitability:
19
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel,
Highlights
The revenue has grown by 11% YoY and by 2.6% from the previous quarter
The gross profit rose by 9% year-on-year
UroGen Pharma's equity has plunged by 101% from the previous quarter
The quick ratio has plunged by 51% YoY and by 28% from the previous quarter
Key stats
What are the main financial stats of URGN
Market
Valuations
Earnings
Shares outstanding
46.26M
Market cap
$1.07B
Enterprise value
$1.1B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
11.68
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.65
Revenue
$94.24M
Gross profit
$83.43M
Operating income
-$123.57M
Net income
-$154.97M
EBIT
-$136.01M
EBITDA
-$134.34M
Free cash flow
-$123.53M
Per share
Balance sheet
Liquidity
EPS
-$3.12
EPS diluted
-$3.12
Free cash flow per share
-$2.59
Book value per share
-$2.03
Revenue per share
$1.97
TBVPS
$4.37
Total assets
$208.72M
Total liabilities
$302.09M
Debt
$125.92M
Equity
-$93.38M
Working capital
$149.32M
Debt to equity
-1.35
Current ratio
4.14
Quick ratio
3.74
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
-142.6%
Gross margin
88.5%
Net margin
-164.4%
Operating margin
-131.1%
Return on assets
-59.4%
Return on equity
N/A
Return on invested capital
-62.3%
Return on capital employed
-84.4%
Return on sales
-144.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
URGN stock price
How has the UroGen Pharma stock price performed over time
Intraday
19.37%
1 week
16.12%
1 month
35.19%
1 year
88.32%
YTD
116.43%
QTD
15.54%
Financial performance
How have UroGen Pharma's revenue and profit performed over time
Revenue
$94.24M
Gross profit
$83.43M
Operating income
-$123.57M
Net income
-$154.97M
Gross margin
88.5%
Net margin
-164.4%
The company's operating income has shrunk by 55% YoY and by 14% QoQ
The operating margin is down by 40% year-on-year and by 12% since the previous quarter
The net income is down by 36% YoY and by 12% QoQ
URGN's net margin is down by 23% year-on-year and by 9% since the previous quarter
Price vs fundamentals
How does URGN's price correlate with its fundamentals
Growth
What is UroGen Pharma's growth rate over time
Valuation
What is UroGen Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
11.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.65
The company's EPS fell by 8% QoQ and by 3% YoY
UroGen Pharma's equity has plunged by 101% from the previous quarter
The price to sales (P/S) is 63% higher than the last 4 quarters average of 6.0 and 24% higher than the 5-year quarterly average of 7.9
The revenue has grown by 11% YoY and by 2.6% from the previous quarter
Efficiency
How efficient is UroGen Pharma business performance
The company's return on sales fell by 27% YoY and by 9% QoQ
The ROA has decreased by 20% from the previous quarter and by 12% YoY
URGN's return on invested capital is up by 9% year-on-year but it is down by 3.7% since the previous quarter
Dividends
What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for URGN.
Financial health
How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 31% lower than its total liabilities
The quick ratio has plunged by 51% YoY and by 28% from the previous quarter
The current ratio is down by 49% year-on-year and by 27% since the previous quarter
The debt to equity has shrunk by 142% YoY but it is up by 50% QoQ
UroGen Pharma's equity has plunged by 101% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.